甲状腺髓样癌分子分型及治疗.pptVIP

Medical Management of Advanced Metastatic Disease ④Targeted therapy Prevention-PD/PGD Acknowledgement Medical Management of Advanced Metastatic Disease ④Targeted therapy Tyrosine kinase inhibitors(TKIs)-- RET, EGFR, VEGFR, and FGFR, MET  Two small-molecule TKIs, vandetanib (Apr 2011) and cabozantinib(Nov 2012), are currently available as approved agents for the treatment of advanced or progressive MTC and provide significant increases in progression-free survival (PFS).  Medical Management of Advanced Metastatic Disease ●Vandetanib--RET, EGFR, VEGFR and EGFR ⅰtwo phase 2 (her